MAP PHARMACEUTICALS
MAP Pharmaceuticals, Inc., a development stage company, focuses on developing novel inhalation therapies for respiratory and systemic diseases. It has various proprietary product candidates in clinical development, including Unit Dose Budesonide for pediatric asthma in children from six months to eight years of age and MAP0004 for migraine. The company's product portfolio also includes MAP0005 for the treatment of adolescent and adult asthma, and chronic obstructive pulmonary disease; and MAP0001 for the treatment of Type 1 and Type 2 diabetes via pulmonary delivery using its Tempo inhaler. MAP Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Mountain View, California.
MAP PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2003-01-01
Address:
Mountain View, California, United States
Country:
United States
Website Url:
http://www.mappharma.com
Total Employee:
51+
Status:
Closed
Contact:
650-386-3100
Total Funding:
105.25 M USD
Technology used in webpage:
SPF SSL By Default Domain Not Resolving Microsoft Azure DNS IIS 10 ASP.NET 4.0 Entrust EV Entrust SSL Cisco Ironport Cloud MarkMonitor DNS
Current Advisors List
Stock Details
Investors List
Skyline Ventures
Skyline Ventures investment in Series D - MAP Pharmaceuticals
Pequot Capital
Pequot Capital investment in Series D - MAP Pharmaceuticals
D. E. Shaw & Co.
D. E. Shaw & Co. investment in Series D - MAP Pharmaceuticals
Perseus
Perseus investment in Series D - MAP Pharmaceuticals
Brookside Capital
Brookside Capital investment in Series D - MAP Pharmaceuticals
Bay City Capital
Bay City Capital investment in Series D - MAP Pharmaceuticals
Perseus
Perseus investment in Series C - MAP Pharmaceuticals
Alexandria Real Estate Equities
Alexandria Real Estate Equities investment in Series C - MAP Pharmaceuticals
Bay City Capital
Bay City Capital investment in Series C - MAP Pharmaceuticals
Skyline Ventures
Skyline Ventures investment in Series C - MAP Pharmaceuticals
